Silence Therapeutics plc
Silence Therapeutics plc (SLN) Revenue
Annual & quarterly revenue history · segment & region breakdown
SLN · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsSilence Therapeutics plc trailing twelve-month (TTM) revenue is $0.00B, a decrease of 98.71% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.04B | -98.71% |
| 2024-12-31 | $0.04B | +$0.02B | +70.47% |
| 2023-12-31 | $0.03B | +$0.01B | +43.74% |
| 2022-12-31 | $0.02B | +$0.01B | +42.19% |
| 2021-12-31 | $0.01B | +$0.01B | +126.59% |
| 2020-12-31 | $0.01B | +$0.01B | +2145.49% |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | -$0.00B | -100.00% |
| 2017-12-31 | $0.00B | -$0.00B | -97.92% |
| 2016-12-31 | $0.00B | +$0.00B | — |
Compare revenue vs peers
BiotechnologyCompare SLN revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Silence Therapeutics plc receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Silence Therapeutics plc reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Silence Therapeutics plc's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
SLN revenue · 4 questionsSLN's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 98.71% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Silence Therapeutics plc SEC filings · GAAP · Silence Therapeutics plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026